A H2AX⁻CARP-1 Interaction Regulates Apoptosis Signaling Following DNA Damage.

CCAR1/CARP-1 apoptosis cancer cells chemotherapeutics γH2AX

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
14 Feb 2019
Historique:
received: 26 12 2018
revised: 07 02 2019
accepted: 10 02 2019
entrez: 17 2 2019
pubmed: 17 2 2019
medline: 17 2 2019
Statut: epublish

Résumé

Cell Cycle and Apoptosis Regulatory Protein (CARP-1/CCAR1) is a peri-nuclear phosphoprotein that regulates apoptosis via chemotherapeutic Adriamycin (doxorubicin) and a novel class of CARP-1 functional mimetic (CFM) compounds. Although Adriamycin causes DNA damage, data from Comet assays revealed that CFM-4.16 also induced DNA damage. Phosphorylation of histone 2AX (γH2AX) protein is involved in regulating DNA damage repair and apoptosis signaling. Adriamycin or CFM-4.16 treatments inhibited cell growth and caused elevated CARP-1 and γH2AX in human breast (HBC) and cervical cancer (HeLa) cells. In fact, a robust nuclear or peri-nuclear co-localization of CARP-1 and γH2AX occurred in cells undergoing apoptosis. Knock-down of CARP-1 diminished γH2AX, their co-localization, and apoptosis in CFM-4.16- or Adriamycin-treated cells. We found that CARP-1 directly binds with H2AX, and H2AX interacted with CARP-1, but not CARP-1 (Δ600⁻652) mutant. Moreover, cells expressing CARP-1 (Δ600⁻652) mutant were resistant to apoptosis, and had diminished levels of γH2AX, when compared with cells expressing wild-type CARP-1. Mutagenesis studies revealed that H2AX residues 1⁻35 harbored a CARP-1-binding epitope, while CARP-1 amino acids 636⁻650 contained an H2AX-interacting epitope. Surface plasmon resonance studies revealed that CARP-1 (636⁻650) peptide bound with H2AX (1⁻35) peptide with a dissociation constant (K

Identifiants

pubmed: 30769864
pii: cancers11020221
doi: 10.3390/cancers11020221
pmc: PMC6406907
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : BLRD VA
ID : I01 BX001164
Pays : United States
Organisme : BLRD VA
ID : IK6 BX004015
Pays : United States
Organisme : U.S. Department of Veterans Affairs
ID : 5I01BX001164-07

Références

J Biol Chem. 1999 Mar 5;274(10):6469-75
pubmed: 10037739
Nature. 2001 May 17;411(6835):342-8
pubmed: 11357141
Nat Rev Cancer. 2002 Apr;2(4):277-88
pubmed: 12001989
J Biol Chem. 2003 Aug 29;278(35):33422-35
pubmed: 12816952
Proc Natl Acad Sci U S A. 2004 May 4;101(18):6864-9
pubmed: 15100411
J Biol Chem. 2006 May 12;281(19):13188-98
pubmed: 16543231
Mol Cell. 2006 Jul 7;23(1):121-32
pubmed: 16818236
Nat Protoc. 2006;1(1):23-9
pubmed: 17406208
Mol Cancer Ther. 2007 May;6(5):1661-72
pubmed: 17513614
FASEB J. 2008 Jul;22(7):2541-51
pubmed: 18245173
Nat Rev Mol Cell Biol. 2008 May;9(5):378-90
pubmed: 18414491
Mol Cell. 2008 Aug 22;31(4):510-9
pubmed: 18722177
J Biol Chem. 2009 Jul 31;284(31):20629-37
pubmed: 19520846
Chem Biol. 2010 May 28;17(5):421-33
pubmed: 20534341
J Nucleic Acids. 2010 Aug 03;2010:null
pubmed: 20811597
J Biol Chem. 2011 Nov 4;286(44):38000-17
pubmed: 21903591
J Mol Cell Biol. 2012 Oct;4(5):294-303
pubmed: 22735644
PLoS One. 2013 Jun 24;8(6):e66733
pubmed: 23826121
Genes Cancer. 2013 Sep;4(9-10):360-8
pubmed: 24349633
Bioinformatics. 2014 Jun 15;30(12):1771-3
pubmed: 24532726
PLoS One. 2014 Mar 05;9(3):e89146
pubmed: 24598827
J Biol Chem. 2014 Jun 13;289(24):17078-86
pubmed: 24811171
PLoS One. 2014 Jul 17;9(7):e102567
pubmed: 25033461
Biomed Res Int. 2014;2014:418458
pubmed: 25610865
Cell Rep. 2015 Mar 3;10(8):1324-34
pubmed: 25732823
Oncotarget. 2015 Mar 30;6(9):6499-510
pubmed: 25894788
J Biomed Nanotechnol. 2015 Sep;11(9):1608-27
pubmed: 26485930
J Chem Theory Comput. 2015 Aug 11;11(8):3696-713
pubmed: 26574453
J Chem Theory Comput. 2013 Jul 9;9(7):3084-95
pubmed: 26583988
J Chem Theory Comput. 2012 Sep 11;8(9):3314-21
pubmed: 26605738
Oncotarget. 2016 Nov 8;7(45):73370-73388
pubmed: 27687593
Oncotarget. 2017 Aug 24;8(62):104894-104912
pubmed: 29285221
Oncotarget. 2017 Sep 5;8(62):104928-104945
pubmed: 29285223
React Oxyg Species (Apex). 2016;2(6):432-439
pubmed: 29707647
Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303
pubmed: 29788355
Oncotarget. 2018 Jul 3;9(51):29680-29697
pubmed: 30038713
Science. 1994 Dec 16;266(5192):1821-8
pubmed: 7997877
Blood. 1998 Aug 15;92(4):1235-46
pubmed: 9694712

Auteurs

Sreeja C Sekhar (SC)

John D. Dingell Veterans Administration Medical Center, Detroit, MI 48201, USA. sreejacsekhar@gmail.com.
Department of Oncology, Karmanos Cancer Institute, Detroit, MI 48201, USA. sreejacsekhar@gmail.com.

Jaganathan Venkatesh (J)

John D. Dingell Veterans Administration Medical Center, Detroit, MI 48201, USA. jaganvibt@gmail.com.
Department of Oncology, Karmanos Cancer Institute, Detroit, MI 48201, USA. jaganvibt@gmail.com.

Vino T Cheriyan (VT)

John D. Dingell Veterans Administration Medical Center, Detroit, MI 48201, USA. vinorcc@gmail.com.
Department of Oncology, Karmanos Cancer Institute, Detroit, MI 48201, USA. vinorcc@gmail.com.

Magesh Muthu (M)

John D. Dingell Veterans Administration Medical Center, Detroit, MI 48201, USA. magesh.research@gmail.com.
Department of Oncology, Karmanos Cancer Institute, Detroit, MI 48201, USA. magesh.research@gmail.com.

Edi Levi (E)

John D. Dingell Veterans Administration Medical Center, Detroit, MI 48201, USA. Edi.Levi@va.gov.

Hadeel Assad (H)

Department of Oncology, Karmanos Cancer Institute, Detroit, MI 48201, USA. Assadh@karmanos.org.

Paul Meister (P)

Department of Chemistry and Biochemistry, University of Windsor, Windsor, ON N9B 3P4, Canada. meisterp@uwindsor.ca.

Vishnu V Undyala (VV)

Cardiovascular Research Institute, School of Medicine, Wayne State University, Detroit, MI 48201, USA. uvreddi@gmail.com.

James W Gauld (JW)

Department of Chemistry and Biochemistry, University of Windsor, Windsor, ON N9B 3P4, Canada. gauld@uwindsor.ca.

Arun K Rishi (AK)

John D. Dingell Veterans Administration Medical Center, Detroit, MI 48201, USA. rishia@Karmanos.org.
Department of Oncology, Karmanos Cancer Institute, Detroit, MI 48201, USA. rishia@Karmanos.org.
Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI 48201, USA. rishia@Karmanos.org.

Classifications MeSH